Annual Report 2014 Active Biotech AB (publ)
April 30 2015 - 4:04AM
Active Biotech's Annual Report 2014 is now available for download
at www.activebiotech.com.
The Annual Report will only be digitally
distributed.
Lund, April 30, 2015 Active Biotech AB (publ)
Tomas Leanderson President & CEO
For further information, please contact: Hans Kolam CFO
Tel +46 (0)46 19 20 44
Active Biotech AB (publ) (Nasdaq
Stockholm: ACTI) is a biotechnology company with focus on
neurodegenerative/inflammatory diseases and cancer. Laquinimod, an
orally administered small molecule with unique immunomodulatory
properties, is in pivotal phase III development for the treatment
of relapsing remitting multiple sclerosis. Also, laquinimod is in
phase II development for the treatment of primary progressive
multiple sclerosis and Huntington's disease. The project portfolio
includes a preclinical project, ISI, with the objective to produce
new, patentable chemical compounds for treatment of diseases within
the company's focus areas. Please visit www.activebiotech.com for
more information.
Active Biotech AB (Corp. Reg. No. 556223-9227)
Box 724, SE-220 07 Lund Tel: +46 46 19 20 00 Fax: +46 46 19 11
00
Active Biotech is required under the Financial Instruments
Trading Act to make the information in this press release public.
The information was submitted for publication at 10:00 a.m. CET on
April 30, 2015.
Annual Report 2014 Active Biotech AB (publ)
http://hugin.info/1002/R/1916577/685362.pdf
HUG#1916577
Actividentity Corp (MM) (NASDAQ:ACTI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Actividentity Corp (MM) (NASDAQ:ACTI)
Historical Stock Chart
From Apr 2023 to Apr 2024
